

---

**VentureAcess Group Limited ABN 42 087 426 953**

**Company notice – NSX Listing Rule 6.13.2**

**Extension of offer period and notification of relevant interests**

---

**To: National Stock Exchange of Australia Limited (NSX)**

VentureAcess Group Limited (**VentureAcess Group**) has extended the offer period for its takeover offers dated 14 August 2008 (which are contained in its bidder's statement dated 14 August 2008) for all of the ordinary shares and nominated share options in Medical Science Australia Limited (**MSA**). The offers will now close at 5:00pm (Sydney time) on 24 October 2008.

VentureAcess Group gives notice under NSX Listing Rule 6.13.2 that:

- a) VentureAcess Group held no relevant interest in MSA shares when the first of the offers was made; and
- b) at the date of the extension, VentureAcess Group had a relevant interest in 51.68% of MSA shares.

**Dated** 26 September 2008

---

**VentureAcess Group Limited ABN 42 087 426 953**

**Company Notice– paragraph 630(2)(b) Corporations Act 2001**

**New date for giving the notice of the status of conditions**

---

**To: Medical Science Australia Limited (MSA);  
and National Stock Exchange of Australia Limited.**

For the purposes of paragraph 630(2)(b) of the Corporations Act 2001, VentureAcess Group Limited (**VentureAcess Group**) gives notice that:

1. the offer period relating to the offers by VentureAcess Group for all of the ordinary shares and nominated share options in MSA, which offers are contained in a bidder's statement dated 14 August 2008 (**Bidder's Statement**), has been extended so that it is now scheduled to close at 5:00pm (Sydney time) on 24 October 2008;
2. the new date for giving the notice of the status of the conditions to the offers, as required by subsection 630(3) of the Corporations Act 2001, is 17 October 2008; and
3. on the date of this notice:

VentureAcess Group has not freed the Offer from any of the conditions of the Offer

Date: 26 September 2008

---

## VentureAcess Group Limited (ABN 42 087 426 953)

### Company notice – subsection 650D(1) Corporations Act 2001

#### Notice of variation – extension of offer period

---

**To: Australian Securities and Investments Commission (“ASIC”);  
Medical Science Australia Limited (“MSA”); and  
Each person to whom offers were made under the takeover bid referred to in  
this notice.**

VentureAcess Group Limited (**VentureAcess Group**) gives notice under subsection 650D(1) of the Corporations Act 2001 that:

1. it varies its takeover offer dated 14 August 2008 (“Offer”) for all of the ordinary shares and nominated share options in MSA which is contained in its bidder’s statement dated 14 August 2008 (**Bidder’s Statement**) by extending the period during which the Offer will remain open so that the Offer will now close at 5:00pm (Sydney time) on 24 October 2008; and
2. the Offer is varied by:
  - a) by amending section 6.9 to read “The date for giving the notice on the status of the conditions referred to in section 6.8 required by section 630(1) of the Corporations Act is 17 October 2008 (subject to extension in accordance with section 630(2) of the Corporations Act if the Offer Period is extended ; and
  - b) replacing “3 October 2008” with “24 October 2008” in section 1.1 of the Bidder’s Statement; and
  - b) replacing “3 October 2008” with “24 October 2008” in section 6.2(1) of the Bidder’s Statement; and
  - b) replacing the definition of Closing Date in section 11.1 of the Bidder’s Statement to read “**Closing Date**” means 24 October 2008, unless the Offer is extended; and
  - b) replacing “3 October 2008” with “24 October 2008” on the Acceptance Form in the Bidder’s Statement.


A copy of this notice was lodged with the ASIC on 26 September 2008. ASIC takes no responsibility for the contents of this notice.

**Dated** 26 September 2008

**Signed** for and on behalf of VentureAcess Group pursuant to a resolution passed at a meeting of directors of VentureAcess Group.



Karalyn Day  
Director and Company Secretary  
Contact: Karalyn Day +61 2 9999 0540



Emyr Jones  
Director